title: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
abstract: OBJECTIVE
  Tumor necrosis factor (TNF) is a pivotal cytokine in intestinal inflammation. Controlled trials using a chimeric anti-TNF antibody (infliximab) have shown its efficacy in refractory Crohn's disease.
  
  
  METHODS
  Endoscopic and histological response to infliximab was investigated in a multicenter, randomized, double-blind, and placebo-controlled trial including 30 patients with active Crohn's disease undergoing ileocolonoscopy before and 4 weeks after intravenous administration of 5, 10, or 20 mg/kg of infliximab or placebo as a single infusion. Lesions were scored by means of the validated Crohn's Disease Endoscopic Index of Severity (CDEIS). Endoscopic biopsy specimens were taken during both procedures from 9 of 30 patients and scored by a single gastrointestinal pathologist.
  
  
  RESULTS
  CDEIS scores decreased significantly in most infliximab-treated patients without an apparent dose response. No endoscopic improvement was observed in the placebo group. The changes in CDEIS correlated highly with those of the Crohn's Disease Activity Index. At a histological level, disappearance of the inflammatory infiltrate was observed in infliximab-treated patients but not in placebo-treated ones; however, architectural changes persisted in most patients. Strictures developed in several patients.
  
  
  CONCLUSIONS
  Clinical improvement after infliximab therapy in active Crohn's disease is accompanied by significant healing of endoscopic lesions and disappearance of the mucosal inflammatory infiltrate.
authors.affiliation: Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium. geert.dhaens@uz.kuleuven.ac.be
authors.forename: G
authors.initials: G
authors.lastname: D'haens
authors.forename: S
authors.initials: S
authors.lastname: Van Deventer
authors.forename: R
authors.initials: R
authors.lastname: Van Hogezand
authors.forename: D
authors.initials: D
authors.lastname: Chalmers
authors.forename: C
authors.initials: C
authors.lastname: Kothe
authors.forename: F
authors.initials: F
authors.lastname: Baert
authors.forename: T
authors.initials: T
authors.lastname: Braakman
authors.forename: T
authors.initials: T
authors.lastname: Schaible
authors.forename: K
authors.initials: K
authors.lastname: Geboes
authors.forename: P
authors.initials: P
authors.lastname: Rutgeerts
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D015331:Cohort Studies; D003424:Crohn Disease / Q000097:blood / Q000473:pathology / Q000628:therapy*; D004724:Endoscopy; D005060:Europe; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein; D000069285:Infliximab